Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pilot Study: Active Video Gaming to Facilitate Physical Activity and Quality of Life in Kidney Transplant Recipients

This study has been completed.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Nova Scotia Health Authority Identifier:
First received: April 20, 2012
Last updated: May 14, 2015
Last verified: May 2015


Renal transplant recipients have a greater risk of morbidity and mortality primarily due to cardiovascular disease when compared to the general population. Cardiovascular disease is responsible for 50% to 60% percent of deaths amongst renal transplant population and death from cardiovascular disease is a leading cause of functioning graft loss.

Physical activity is an effective form of secondary prevention in existing cardiovascular disease reducing all-cause mortality by 25%-30% and has demonstrated positive effects overall on quality of life and well-being. Transplant patients who participated in regular cardiovascular exercise have significant more positive scores on the SF-36 Health Status Questionnaire in comparison to inactive transplant recipients.

Active video gaming is evolving as an innovative method to increase physical activity. Active video gaming has supported physical activity in children and youth. There is however a paucity of literature examining interactive games as a means to facilitate physical activity and its impact on CVD and quality of life in the adult population nor any literature examining AVG and its impact on an adult surgical population.

This pilot study is designed to determine if Active Video Gaming is feasible and is able to lead to behavioral modifications and Quality of Life improvement.

Subject Selection:

This is a pilot study during which 10 patients who have undergone renal transplant will be selected to exercise with Active Video Gaming for a duration of 3 months. The program activity will begin 6 months post surgery.

Condition Intervention Phase
Quality of Life
Behavioral: Workout based on active video gaming
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Official Title: Pilot Study: Active Video Gaming to Facilitate Physical Activity and Quality of Life in Kidney Transplant Recipients

Resource links provided by NLM:

Further study details as provided by Nova Scotia Health Authority:

Primary Outcome Measures:
  • Quality of Life [ Time Frame: 3 months post intervention ] [ Designated as safety issue: No ]
    Quality of life will be measured at baseline and upon completion of the intervention using a standard questionnaire.

Estimated Enrollment: 10
Study Start Date: June 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active Video Gaming
An active gaming exercise workout will be provided with QoL measured at baseline and following the 8 week workout schedule. The workout will use the Microsoft Kinect (TM) system with EA Sports Active 2 program.
Behavioral: Workout based on active video gaming
A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
Other Names:
  • Microsoft Kinect
  • EA Sports Active 2


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Renal transplant patient who want and are able to take part in this study

Exclusion Criteria:

  • Cardiac or pulmonary dysfunction diagnosed through preoperative assessment.
  • Any surgical complication incurred with transplantation.
  • Peripheral vascular disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01583257

Canada, Nova Scotia
QEII Health Sciences Center, MOTP
Halifax, Nova Scotia, Canada, B3H 2Y9
Sponsors and Collaborators
Nova Scotia Health Authority
Novartis Pharmaceuticals
Principal Investigator: Ian P Alwayn, MD, PhD CDHA / Dalhousie University
  More Information

Responsible Party: Nova Scotia Health Authority Identifier: NCT01583257     History of Changes
Other Study ID Numbers: CDHA-AVG2012 
Study First Received: April 20, 2012
Last Updated: May 14, 2015
Health Authority: Canada: Ethics Review Committee processed this record on October 21, 2016